DALGLEISH, ANGUS GEORGE,SMITH, PETER MICHAEL,SUTTON, ANDREW DEREK,WALKER, ANTHONY IAN
申请号：
CA2354045
公开号：
CA2354045C
申请日:
1999.12.09
申请国别(地区):
CA
年份:
2012
代理人:
摘要：
The invention here relates to a product comprised of a cell line or linesintended for use as an allogeneic immunotherapy agent for the treatment ofcancer in mammals and humans. All of the studies of cell-based cancer vaccinesto date have one feature in common, namely the intention to use cells thatcontain at least some TSAs and/or TAAs that are shared with the antigenspresent in patients' tumour. In each case, tumour cells are utilised as thestarting point on the premise that only tumour cells will contain TSAs or TAAsof relevance, and the tissue origins of the cells are matched to the tumoursite in patients. A primary aspect of the invention is the use of immortalisednormal, non-malignant cells as the basis of an allogeneic cell cancer vaccine.Normal cells do not possess TSAs or relevant concentrations of TAAs and henceit is surprising that normal cells are effective as anti-cancer vaccines. Forprostate cancer, for example, a vaccine may be based on one or a combinationof different immortalised normal cell lines derived from the prostate. Thecell lines are lethally irradiated utilising gamma irradiation at 50-300 Gy toensure that they are replication incompetent prior to use in the mammal orhuman.
